Table 2 Change from Baseline in sleep measures at week 12
Scale | ASTERIA I | ASTERIA II | GLACIAL | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Placebo | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo | Omalizumab 300 mg | |
MOS-Sleep Scale, SPI-II, n | 63 | 67 | 63 | 72 | 70 | 70 | 70 | 73 | 62 | 217 |
Mean (SD) | −1.7 (18.0) | −14.4 (18.6) | −11.8 (20.6) | −18.1 (21.6)* | −10.8 (16.7) | −15.5 (20.0) | −16.4 (15.4)* | −16.8 (19.4)* | −13.4 (15.8) | −19.0 (20.5)*** |
UPDD Weekly Sleep Interference Score, n | 62 | 64 | 63 | 73 | 69 | 68 | 73 | 74 | 67 | 214 |
Mean (SD) | −5.0 (5.3) | −7.0 (5.6) | −7.1 (6.0)* | −9.6 (5.3)** | −6.2 (5.7) | −6.8 (6.7) | −7.8 (6.4) | −9.2 (5.8)** | −5.0 (6.5) | −9.2 (5.3)** |
CU-Q2oL Sleep Problems domain, n | 49 | 50 | 48 | 57 | 62 | 59 | 61 | 65 | 60 | 210 |
Mean (SD) | −18.8 (23.5) | −20.5 (21.6) | −22.1 (25.4) | −30.2 (23.8) | −18.0 (24.2) | −22.6 (23.4) | −25.2 (26.4) | −33.3 (24.9)** | −18.3 (22.2) | −29.4 (23.8)** |